CRANBURY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio were re-elected at the 2016 Annual Meeting of Stockholders.
John F Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to welcome Craig to Amicus. He has overseen the advancement and commercialization of a wide range of biopharmaceuticals for a variety of indications, and successfully led Momenta’s transformation to a commercial-stage company while growing and diversifying the Company’s development pipeline. His experience and insights will be invaluable to Amicus during our initial product launch as a commercial company and as we build out our biologics manufacturing capabilities. I look forward to working with Craig as we advance our pipeline of novel, potentially best-in-class therapies for people living with rare and devastating diseases.”
Mr. Wheeler has extensive experience in leading biopharmaceutical companies to advance a wide range of treatments for serious diseases. He is currently President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also serves on the board of directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. He has also overseen the company’s growth into a diversified business, with a development pipeline of biosimilar biologics as well as novel therapeutics for oncology and autoimmune indications. Prior to Momenta, Craig worked at Chiron Corporation as President, Chiron BioPharmaceuticals (now Novartis Vaccines & Diagnostics). Prior to joining Chiron, Craig was a senior member of The Boston Consulting Group's health care practice. Mr. Wheeler also worked for Merck's MSDRL research unit, where he served as a senior engineer in process development and at Hybritech as a financial analyst.
Mr. Wheeler previously served for nine years as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. He also served as GPhA’s Chairman of the Board of Directors from 2014 to February 2016. In 2011 Mr. Wheeler was an E&Y Entrepreneur of the Year Regional Award winner. He holds a BS and an MS degree in chemical engineering from Cornell University, and an MBA from the Wharton School of the University of Pennsylvania.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other lysosomal storage disorders.
FOLD–G